# A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . .

> **NCT00451867** · PHASE3 · TERMINATED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 210 (actual)

## Conditions studied

- Interstitial Cystitis
- Painful Bladder Syndrome

## Interventions

- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Mycofenolate Mofetil (MMF)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00451867
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-03
- **Primary completion:** 2008-02
- **Final completion:** 2008-04
- **Target enrollment:** 210 (ACTUAL)
- **Why stopped:** The major and primary reason for the study termination is the observed reduced efficacy of CellCept compared to placebo.
- **Last updated:** 2010-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00451867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00451867, "A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . .". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00451867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*